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ABSTRACT 
According to the National Center for Health Statistics, an estimated 22 million women have 
undergone a hysterectomy procedure in the United States. The most common complication 
during hysterectomies is accidental laceration of the urinary bladder during the surgery with 
incidence between 0.2-8.3% with the current gold standard wound repair method being 
sutures. Yet, sutures come with their own limitations in that they necessitate use of a 
catheter and collection bag during healing due to preventing proper distention of the bladder 
tissue at normal pressures. The long-term goal of our study is to eliminate the need for 
suturing by creating a surgical adhesive that provides a combination of strength, 
compliance, and biocompatibility for application to the bladder. However, current FDA-
approved, commercially available tissue adhesives and sealants each have specific 
limitations that make them unsuitable for bladder application. While addressing the 
shortcomings of its predecessors, poloaxmines called Tetronic® (BASF Corporation) have 
been used as the backbone of a novel tissue adhesive. Previous studies using Tetronic® have 
exhibited higher strengths with increasing hydrogel content, but need further refinement to 
meet the mechanical requirements for bladder wall tissue mechanics. Thus, it is 
hypothesized that incorporation of a low molecular weight poloaximine, Tetronic® 304 
(T304, MW: 1650 Da) would allow further increasing of hydrogel content and could yield 
higher bonding and bulk strength for a tissue adhesive while not compromising gelation 
time. Briefly, Tetronic® 304, and 1107 (MW: 15030 Da) were reacted with acryloyl 
chloride to form terminal acrylate groups using previously established methods with the 
final product characterized through NMR spectroscopy to determine the acrylation 
iii 
 
conversion percentage. The Tetronic® acrylate was crosslinked using dithiothreitol (DTT) 
with the bulk strengths of various blends of the Tetronic®-based adhesive determined via 
calculating maximum tensions from end-to-end tensile adhesion tests on collagen sheets. In 
addition, punctured rat bladder specimens sealed with two blends of the hydrogel adhesive 
were subjected to increasing intravesicular pressure until failure.  
 
The maximum tension achieved from the tensile tests was for the 75/25 at 60wt% T304-
acrylate/T1107-acrylate group with a value of 0.65 N/cm ±0.06 N/cm (n=6). In addition, the 
rat bladder puncture sealed with a 50/50 blend at 50wt % withstood pressure at an average 
of 45.45±3.96 cm H2O. These results have demonstrated that using T304 has allowed for a 
higher content of hydrogel to be incorporated into the Tetronic®-based adhesive, thus 
increasing overall bulk strength. To further test the efficacy of this Tetronic®-based 
adhesive, testing the hydrogel-based adhesive on the bladder both ex vivo and in vivo using 
larger animal models will be necessary before moving onto clinical trials 
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CHAPTER ONE 
LITERATURE REVIEW 
A. Clinical Motivation 
 
According to the National Center for Health Statistics, 617,000 hysterectomies were 
performed in 2004, and an estimated 22 million women have undergone this procedure in 
the United States.
1
 Overall, an average of 622,000 hysterectomies have been performed in 
the last decade nationally.
2 
The most common complication during hysterectomies is 
accidental laceration of the urinary bladder during the surgery with incidence between 0.2-
8.3%.
1 
Currently, the gold standard wound repair method for such injuries is suturing. Yet, 
sutures come with their own limitations in that they necessitate use of a catheter and 
collection bag during healing because they prevent proper distention of the bladder tissue 
at normal pressures. Moreover, the uses of catheters can decrease overall patient quality of 
life. Thus, an alternative approach for effective sealing of wounds is being investigated in 
the present study. 
 
B. Urinary Bladder Mechanics 
When considering the suitability of a tissue adhesive for bladder application, it is essential 
to understand the mechanical demands of the urinary bladder. Primary functions of the 
urinary bladder are to contain large volumes of urine at low pressures
3
 and to void upon 
smooth muscle contraction when bladder capacity is reached.
4,5
 The mechanical behavior 
of the bladder wall tissue is reliant on the properties of smooth muscle cells and the 
2 
 
extracellular matrix for their contractile function and tensile properties, respectively.
5,6
 
Specifically, the microstructure, the interaction of the tissue components, and the resulting 
overall response of the tissue changes from moment to moment.
7
 In one study, Nagatomi 
et al. found that compared to normal rat bladders, 3-week spinal cord injury (SCI) rat 
bladders exhibited a decrease in collagen content by 43%, and an increase in elastin 
content by 260%, which explained the increased compliance of SCI rat bladders.
8,9
 
Subsequent studies found that spinal cord injury (SCI) in rats prompted smooth muscle 
hypertrophy (p<0.05) and changes in muscle orientation.
6
 While normal rat bladders 
exhibited smooth muscle direction mostly in the longitudinal direction, 10 days after 
spinal cord injury smooth muscles oriented in both the longitudinal and circumferential 
direction.
6 
Toosi et al. expanded the scope of the experiment from 10 days to 10 weeks, 
reporting changes in the biomechanical response of the urinary bladder wall tissue went 
further than changes in overall bladder compliance. Particularly, changes in material class 
from anisotropic (in normal rats) to isotropic (in 10-day SCI rats) to anisotropic (in 10-
week SCI rats), bladder composition (more collagen present in SCI rats), and architecture 
(smooth muscle orientation from longitudinal to bimodal) were observed, indicating 
constant remodeling of bladder wall tissue after the initial injury.
10
 
 
Although mechanical testing of the bladder at the tissue level has provided valuable 
information about its functional state
8
, the mechanical behavior of the whole bladder is 
governed not only by the tissue properties, but also by bladder shape and size.
11
 Testing of 
the whole bladder will further elucidate the physiological nature of its smooth muscle and 
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ECM components under loading in vivo.
5
 Damaser and Lehman were the first to use 
mathematical modeling and experimental data from dog bladders in vivo to predict the 
effects of bladder shape on the pressure–volume relationship.3 They established 
equilibrium equations for two types of spheroids: prolate and oblate to predict stress, 
strain, and volume of the bladder tissue at various pressures. The oblate spheroid (Figure 
1.1) made of urinary bladder material was shown to be more compliant than a prolate 
spheroid or sphere. Defining bladder capacity as the volume of the bladder at the greatest 
pressure (22 cm H2O in this study; normally between 20-60 cm H2O), oblate spheroids 
had up to 70% more capacity than other models of the bladder.
3
 Greater bladder 
compliance indicates a greater capacity to distend in response to pressure without 
disruption. Since the use of sutures for wound repair restricts proper distension of the 
whole bladder at normal physiological pressures, an alternative method of wound repair is 
necessary. 
 
Figure 1.1: Oblate Spheroid Model of Urinary Bladder 
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C. Tissue Adhesives 
Today’s most common methods for wound closure are sutures and surgical staples despite 
a variety of limitations, including risk of infection, the requirement for anesthesia, and 
difficulty in application and retention in soft tissues. These shortcomings in current 
methods have led to the development of polymeric tissue adhesives that are capable of 
being cured in situ.
12
 Tissue adhesives are defined as any substance that either acts as a 
tissue connector or as a barrier for leakage. 
 
In the past, tissue adhesives were only used in conjunction with sutures during wound 
closure procedures.
13 
However, in order for surgical adhesives to serve as a viable 
alternative to sutures and staples, they need to exhibit the ability to rapidly adhere as well 
as maintain a close proximity to edges of wounds for an appropriate period of time.
14
 In 
addition, an effective tissue adhesive should possess strong binding strength, ease of 
application, biocompatibility with tissue, minimal reactivity with tissue, and practical cost 
.
15 
Moreover, hemostatic potential, infection control capability, and internal sealant 
bonding strength will add value to the tissue adhesives.
16
 An adhesive can furthermore 
serve as a temporary scaffold while new tissue remodels the wound over the course of 
time.
12
 
 
D. Current Types of Tissue Adhesives 
Although not specifically approved for urological applications, a variety of FDA-approved 
adhesives and sealants are currently available on the market for surgical purposes. Major 
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varieties of these include cyanoacrylates, BioGlue, fibrin glues, polyethylene-glycol 
(PEG) based hydrogels.
13
 Additionally, collagen-based hydrogels are less commonly used, 
but emerging as a viable option.
13
 These types of tissue adhesives have been thoroughly 
analyzed as hemostatic agents and sealants in animal models as well as in clinical studies 
of urinary fistula, cystotomy, and partial nephrectomy.
17,18
 Although there are benefits to 
each of these tissue adhesive substances, there are noteworthy drawbacks such as 
mismatch between the mechanical properties of the adhesives and native tissue, 
complications related to residual toxicity, and difficulties with crosslinking. 
a. Cyanoacrylate 
Cyanoacrylate or “super glue” was first used as a tissue sealant in the 1940s, but its use 
was limited due to the high levels of inflammation and histotoxicity it caused.
17
 The first 
cyanoacrylate tissue adhesive was used for minor lacerations, but had limited physical 
properties. Later, with further improvement, cyanoacrylate adhesives were used in 
treatments for cornea perforation and wound leak keratotherapy
19
,
 
as well as in facial 
plastic and reconstructive surgery.
15
 
 
In addition to reconstructive surgery, cyanoacrylates are generally used as an alternative to 
suture closure. Cyanoacrylates are hard and brittle and may have insufficient flexibility for 
the vibrant nature of in vivo conditions. Thus, these polymers are only used in external 
applications such as skin closure and repair of corneal perforations.
14
 However, they do 
possess numerous favorable characteristics including their ability to rapidly form flexible 
bonds, act as an occlusive protective dressing, decrease inflammation, and ease of 
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application. Many studies have noted that cyanoacrylate application only takes between 
30-60% of the time as suture repair.
15
 
 
Methyl-2-cyanoacrylate was the first cyanoacrylate compound to be used as a surgical 
tissue adhesive.
15 
Over the years, histotoxicity levels of this adhesive have been shown to 
be proportional to the length of their monomer side chain.
15
 More specifically, the toxic 
effect of synthetic polymers is linked to types of breakdown products and the release 
rate.
19
 Newer cyanoacrylate-based tissue adhesives, such as butyl-2-cyanoacrylate, have 
longer side-chain derivatives, and thus, undergo a slower release and more efficient 
clearing of the toxic byproducts from the local tissue.
15
 Moreover, the usage of inhibitors 
of prostaglandin H synthetase, such as aspirin and indomethacin, has been shown to 
decrease the cytotoxicity of cyanoacrylates up to eightfold in vitro.
20
 
 
Today, the most widely used type of cyanoacrylate is octyl-2-cyanoacrylate, which was 
approved by the FDA for use in topical wound closure in 1998.
15
 There are only two 
cyanoacrylate brands currently authorized for use in the United States: Dermabond 
(Ethicon, Inc.), a octyl-2-cyanoacrylate and Trufill n-BCA (Cordis Neurovascular, Inc.), a 
combination of n-butyl cyanoacrylate and tantalum powder.
13
 Studies have shown that 
tissue injury occurs because of cyanoacrylates’ poor compliance which motivated the use 
of etheric oxygen to allow for the production of flexible monomers, enabled chain 
rotation, and improved adhesive strength.
14
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b. BioGlue 
The next major group of tissue adhesives is based on the combination of purified bovine 
serum albumin and glutaraldehyde glue, and is known as BioGlue (CryoLife Inc).
13
 It is a 
proprietary FDA-approved (2000) compound generally used as a sealant aid to standard 
methods of hemostasis in adults undergoing vascular surgery.
17
 At this time, BioGlue is the 
only compound used in the United States for the restricted use of assisting in the repair of 
aortic dissection by filling in the dissection; thereby closing the open cavity and providing 
a stronger arterial wall.
13
 Strong bonds are created by the glutaraldehyde, which initiates 
chemical reactions between the aldehyde groups of glutaraldehyde and the amine groups, 
particularly lysine, of the albumin and tissue surfaces.
21
 More specifically, glutaraldehyde 
links the amine groups from the bovine serum albumin to extracellular matrix proteins of 
the target tissue, thus creating a covalent bond between the tissue and surgical adhesive.
17
 
 
Although when compared with other similar currently available product, BioGlue has 
greater bonding and sealing capabilities
22
, it does have limitations as well. For example, 
researchers always consider possible tissue-related toxicity as a major drawback.
17 
In one 
study, polymerized BioGlue with saline solution contained 100-200 µg/ml of 
glutaraldehyde and was shown to be cytotoxic to both cell lines used. When BioGlue was 
applied to a partial lung resection model, minimal edema and necrosis were present after 2 
days and severe inflammation was apparent after 7 days.
23
 Other safety issues include local 
tissue necrosis, pseudoaneurysm formation, and risks of eye, nose, throat, and skin 
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irritation from the presence of glutaraldehyde.
21
 Moreover, LeMaire et al. reported that 
BioGlue reinforcement in pigs impairs vascular growth and causes stricture when applied  
circumferentially around an aorto-aortic anastomosis.
22 
Therefore, it was concluded that 
since the use of polymerized BioGlue releases high amounts of toxic, residual 
glutaraldehyde when not used on the aorta, it should not be used in pediatric patients until 
further studies are conducted.
22,23
 It was also noted that even when BioGlue appears to 
present many positive features as a product, the significant toxic potential of the glue 
should be evaluated carefully.
23
 Finally, the inflammatory effects and long-term reaction to 
BioGlue need to be better described and tested before the FDA will approve the further 
expansion of its application.
13 
 
c. Fibrin Glue 
The use of fibrin as an adhesive was first reported in 1940 by Young and Medawar, who 
applied it as an adjunct to sutures of the peripheral nerves in an animal model during 
microsurgery, and then subsequently by Seddon and Medawar in humans.
24
 Since 1998, 
fibrin glue products, which are composed of thrombin and fibrinogen, have been approved 
by the FDA for use in the reinforcement of colonic anastomoses, splenic trauma, and 
cardiothoracic surgery.
17
 Fibrin sealants meet the requirements of an ideal tissue adhesive 
to the greatest extent because both the adhesive and its resulting degradation products are 
biocompatible and have properties that offer topical hemostasis, provide tissue 
approximation, and possess sealant properties.
13,17,25
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Current brands of fibrin glues available in the United States are local blood bank products 
as well as the commercial products, Hemaseel APR (Haemacure Corp.) and Tisseel VH 
(Baxter Healthcare Corp.).
13 
Both products use human thrombin and aprotinin as an 
antifibrinolytic agent.
15 
Like cyanoacrylates, fibrin glues are used to treat corneal injuries, 
such as perforations and ulcers.
26
 When compared, 79% of eyes had successful healing of 
corneal perforation treated with fibrin glue and 86% eyes treated with N-butyl-2-
cyanoacrylate, indicating that both tissue adhesives are effective in the closure of corneal 
perforations up to 3 mm in diameter.
26
 While fibrin glue displayed faster healing and 
generated less corneal vascularization than the cyanoacrylate, it required a much longer 
time for adhesive plug formation.
26 
 
d. PEG Hydrogels 
The final major category of current commercially available tissue sealants is polyethylene 
glycol (PEG) hydrogels. Synthetic hydrogels, such as PEG-based polymers, can drastically 
improve the support of soft tissue organs e.g. the heart or hard tissues e.g. bone.
27
 PEG 
hydrogels as a whole are readily functionalized, nontoxic, non-immunogenic, and blood 
compatible.
28
 Some commercially available PEG-based sealants are made up of PEG diols 
modified with ester linkages that are degradable by water, and terminal acrylates for 
photopolymerization.
12
 They are used for a vast array of clinical applications such as tissue 
regeneration, drug delivery, coating, and postoperative adhesions prevention.
28
 In addition, 
PEG hydrogels are used in research applications, such as model scaffolds for cell 
migration.
29
 
10 
 
CoSeal (Cohesion Technologies, Inc.) and AdvaSeal-S (Genzyme Corp.) are both PEG-
based sealants approved by the FDA in 2000 for use as pulmonary sealants and as an 
additive to blood hemostasis.
17,21 
CoSeal has demonstrated the ability to form adhesive 
bonds with PTFE grafts and biological tissues in vitro while simultaneously exhibiting good 
tissue compatibility and rapid gelation.
30
 Its efficacy has been demonstrated in that 
hemostasis was achieved within 10 minutes in 86% of 148 patients in need of vascular 
sealing.
21
 Another PEG-based sealant, Duraseal, is approved for dural sealing and forms a 
hydrogel when its PEG ester component combines with trilisine amine with FD&C blue No. 
1 dye, thus creating a water tight seal.
21
 Duraseal was shown to be 100% successful in 
preventing cerebrospinal fluid leaks from dural closures.
21
 Reported tensile strengths have 
demonstrated that both CoSeal and Duraseal are suitable as sealants for internal organs, 
specifically arteries.
30
 
 
Although PEG hydrogels are effective in sealing tissue, there are some associated 
shortcomings as well. The primary safety concern of PEG-based sealants is swelling. 
Because PEG hydrogels are water-based, they continue to absorb water and swell in vivo, 
relative to initial volume dispersed.
12,31
 CoSeal swells up to 400% and is therefore never 
used in place of sutures, staples or other mechanical closures. It is also not used in doses of 
more than 16 milliliters since the safety of larger doses has not yet been verified.
21
 
Comparatively, Duraseal only swells to 50%, but may be associated with other 
complications such as inflammatory and allergic reactions if there is a known allergy to its 
blue dye.
21,32
 Another limitation of PEG-based hydrogels lies in that they may contain a 
11 
 
water-soluble agent that requires a light source to polymerize and activate adhesion.
13
 This 
photoactivation, a time-consuming process, makes these hydrogels difficult to work with for 
surgeons in situations where immediate curing is required (i.e. massive hemorrhaging). 
However, newer PEG hydrogels, such as CoSeal do not require this activation source.
13
 
 
Recently, swellable PEG amine/dextran aldehyde composite materials have emerged as 
controlled, biocompatible tissue adhesives.
28 
Together, the authors concluded that 
PEG:dextran hydrogels can effectively adhere to tissue in a tunable manner, while not 
compromising biocompatibility.
28
 
 
E. Use of Tissue Adhesives in Urological Applications 
Tissue adhesives have been tested in urological applications such as cystotomies and partial 
nephrectomies with varying levels of success in both humans and animals.
17
 
a. Cyanoacrylate 
Studies related to urologic applications for cyanoacrylate-based adhesives have yielded 
mixed results. For example, Grummet et al. concluded 2-octyl cyanoacrylate is not fit to be 
used singularly for vesicourethral anastomoses during radical retropubic prostatectomy in 
mongrel hounds.
33
 In contrast, Seifman and colleagues found that 2-octyl cyanoacrylate 
was appropriate for closure of a large cystotomy in a rabbit model while demonstrating an 
inflammatory response similar to traditional suture sealing.
34
 Although 2-octyl 
cyanoacrylate (OCG) has been withheld from areas subject to repetitive movement (such as 
the bladder), its performance in sealing large bladder wounds on pigs was proven to not be 
12 
 
affected by changing bladder volumes during normal filling.
35
 However, a disadvantage of 
OCG was found in its low rate of biodegradability and potential to cause callus 
formations.
35 
 
b. BioGlue 
BioGlue’s role in urological applications has not been assessed to date. However, 
researchers hypothesize that it may prove to be beneficial in controlling bleeding in 
procedures where chronic inflammation is present as well as in procedures where major 
blood vessels need to be exposed, such as post-chemotherapy retroperitoneal 
lymphadenectomies.
17
 Yet, there is the worry that application of BioGlue could cause 
urinary obstruction.
36 
 
c. Fibrin Glue 
Fibrin glue has been used as a sealant in a variety of urological applications such as 
sutureless colposuspension in patients with stress incontinence and as an aide to hemostasis 
in partial nephrectomy.
25
 It has also been used to close bladder fistulae and displayed 
comparable results to microsurgery when treating vasovastotomies.
24
 The use of fibrin glue 
for ureteral surgery has also been assessed in a number of animal models. For example, 
Barrieras et al. performed a pyeloplasty in a porcine model using a suture-assisted fibrin 
glue anastomosis. The immediate anastomotic leak point pressure was significantly lower 
in the fibrin group (3.5 ±1.5 mm Hg) versus the control (17.3±5.4 mm Hg; P = 0.038).
17
 
 
13 
 
Marcovich and associates compared 2-octyl cyanoacrylate (OCG), fibrin glue (FG), and 
sutures for both open and laparoscopic repair of bladder wounds, using a pig model of 
cystotomy. Their results showed that at 4 weeks, none of the six bladders of pigs treated 
with OCG leaked at less than 200 mmHg pressure. In contrast, of the six pigs treated with 
FG, three died from a huge urine leak, one leaked, and two did not leak at less than 200 
mm Hg at 4 weeks. From these findings, it was concluded that OCG is the only viable 
alternative to sutures for sealing of large bladder wounds and fibrin glues may be effective 
in bladder injury closure when tissue approximation is small and intraluminal pressures are 
low.
35
 However, it was also noted that reduction in adhesive capacity upon contact with 
urine due to fibrinolytic activity of urokinase would remain one of the concerns associated 
with the use of fibrin glue in urological applications.
25 
 
d. PEG Hydrogels 
PEG hydrogels have been tested in porcine laparoscopic partial nephrectomy (LPN) models 
and provided hemostasis at physiological pressures up to 100 mmHg.
37
 In addition, Park and 
colleagues found that PEG hydrogels provided hemostasis for LPN in a porcine model and 
detected no cell-mediated immune responses to the sealant after 2 weeks, with the hydrogel 
being completely absorbed by the animal within 6 weeks.
38
 However, compared to fibrin 
glue, the PEG hydrogel-based CoSeal did not adhere as well to the nephrectomy bed during 
LPN, signifying that further refinements need to be made before synthetic hydrogel sealants 
are suitable for urological applications.
36 
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F. Use of Tetronic® as a Tissue Adhesive 
In order to address the issues associated with currently available tissue adhesives and 
sealants, Cho et al. began exploring thermosensitive polymers called poloxamines or 
Tetronic® (BASF Corp.) as the backbone material of a soft tissue adhesive.
12 
Poloaxmines 
are a family of 4-arm polypropylene oxide (PPO) - polyethylene oxide (PEO) block 
copolymers with a hydrophobic PPO core surrounded by a hydrophilic PEO shell and can be 
used to prevent swelling of hydrogel-based tissue adhesives.
12,38
 Previously, Tetronic® was 
studied as a network material to encapsulate human foreskin fibroblasts by way of “tandem 
gelation”, a two-stage process combining reverse, thermally-induced gelation and covalent 
crosslinking of termini functionalized with reactive groups.
40,41
 A study by Cho et al. tested 
a hypothesis that the combination of noncovalent and covalent gelation of Tetronic® 
hydrogels would provide an improvement for mechanical properties of tissue 
sealant/adhesive applications compared to PEG-based hydrogels that were created only by 
covalent crosslinking.
12
 Specifically, Tetronic® 1107 (T1107; MW 15,030 Da) and 
Tetronic® 904 (T904; MW 6700 Da) were acrylated via dichloromethane and acryloyl 
chloride and polymerized by Michael-type addition.
12
 Both hydrogels, T1107-acrylate and 
T904-acrylate, were then characterized for mechanical and tissue bonding properties, 
gelation point, swelling behavior, viscosity, and cytotoxicity.
12
 The results of this study 
provided evidence that all blends (100% T1107-acrylate, 75/25 T1107-acrylate/T904-
acrylate and 50/50) containing T1107-acrylate chemically crosslinked below physiological 
temperatures (37°C), while 100% T904-acrylate and the control 4-arm acrylated PEG did 
not gel within the temperature range of 4-40°C. Gelation time increased with decreasing 
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T1107-acrylate content (23.5±2.12 s for 100% T1107; 153.33±5.77 s for 100% T904). The 
stiffness and strength of Tetronic® hydrogels were greater than the PEG control and 
increased with increasing temperature and T904-acrylate content to a maximum value of 
400 kPa at 37°C. Tissue bonding strength also increased with increasing T904 content 
(maximum of 25 kPa), which was comparable to commercial fibrin glue and far exceeded 
the control PEG hydrogel.
12 
Together, it was concluded that all mechanical properties of the 
hydrogels were temperature dependent and that using tandem gelation contributed positively 
to material properties. 
 
More recently, Barrett et al. reported that Tetronic® backbones terminated with catechols 
including gluataric anhydride, pyridine, dopamine and TEA, served to increase both 
adhesive and cohesive strengths of the hydrogel tissue adhesive.
41
 Briefly, the results of lap 
shear testing revealed that strength values for modified Tetronic® 1107-acrylate gels with 
varying levels (150-250 ml/mg) of these catechols ranged from 31.9-48.7 kPa, which was 
marginally stronger than a DOPA-modified PEG (30.4 ± 3.39 kPa) from a previous study.
42
 
However, the adhesive strength was much higher than that of the catechol-modified 4-arm 
PEO control (12.7 kPa).
41
 Although the highest lap shear adhesive strength from this study 
is well above the mean value reported by Cho et al. (25 kPa)
 
, when comparing results 
parameters such as testing methods, crosslinking mechanisms, and equipment must be taken 
into account.
12,41
 For example, Cho et.al and Barrett et al. both used lap shear testing on 
animal specimens. However, Cho’s samples were subject to overnight curing at 37°C in a 
humidified atmosphere and soaked in PBS before testing.
12
 In contrast, Barrett’s samples 
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were initially cured for one hour at 37°C while glued to aluminum fixtures and covered by 
PBS-soaked gauze.
41
Additionally, a 100 gram weight was placed on the aluminum fixture 
assembly after which the samples were submerged in PBS for one hour before testing.
41 
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CHAPTER TWO 
PROJECT RATIONALE 
The long-term goal of our study is to eliminate the need for suturing by creating a surgical 
adhesive that provides a combination of strength, compliance, and biocompatibility for 
application to the bladder. However, current FDA-approved, commercially available tissue 
adhesives and sealants each have specific limitations that make them unsuitable for bladder 
application. While addressing the shortcomings of its predecessors, the more recent attempt 
to use poloaxmines as the backbone of a novel tissue adhesive needs further refinement to 
meet the mechanical requirements for bladder wall tissue mechanics. Given that the lower 
molecular weight T904-acrylate exhibited higher strengths with increasing hydrogel 
content, it is hypothesized incorporation of an even lower molecular weight poloaximine 
would allow further increasing of hydrogel content and could yield higher bonding and 
bulk strength for a tissue adhesive. This Master’s thesis focused on increasing the overall 
bulk strength of the Tetronic® adhesive by using a low molecular weight Tetronic® 304 
(T304, MW: 1650 Da), while not compromising the strength and gelation time. This study 
is divided into three project aims: 
1) To develop a synthesis route for T304-acrylate with high conversion efficiency 
and product yield. 
2) To determine blend ratios and weight percentage of T304-acrylate and T1107-
acrylate with the highest mechanical strength. 
3) To demonstrate the efficacy of the Tetronic® tissue adhesive in an ex vivo bladder 
test. 
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CHAPTER THREE 
MATERIALS AND METHODS 
A.  Materials 
Tetronic® T1107 (MW 15030 Da) and T304 (MW 1650 Da) were acquired from the BASF 
corporation (USA) as free samples. Acryloyl chloride, celite fine 500 and 4-methoxyphenol 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Toluene (HPLC grade), 
anhydrous ether (BHT stabilized), hexanes (HPLC grade), and anhydrous sodium sulfate 
were purchased from Fisher Scientific (NJ, USA). Dichloromethane (HPLC grade), 
triethylamine (TEA), dithiothreitol (DTT), sodium bicarbonate, calcium hydride and CDCl3 
were purchased from Acros Organics (NJ, USA), a branch of Fisher. Dichloromethane was 
dried with calcium hydride and stored over molecular sieves (Grade 514, Type 4A, 8-12 
mesh, Acros Organics). 
 Table 3.1: Characteristics of specific Tetronics 
Tetronic 
Type 
Molecular 
Weight (Da) 
Mean 
Number of 
EO Units per 
PEO Block 
Mean 
Number of 
PO Units per 
PPO Block 
Physical 
State at 25°C 
(RT) 
T304 1650 3.7 4.3 
Liquid 
T1107 15030 60 20 
Powder 
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Figure 3.1: General Structure of Tetronic® Acrylate.  
Blue boxes indicate terminal acrylate groups 
 
B. Acrylation of Tetronic® 
a. Preparation of T1107-acrylate 
Acrylated T1107 was prepared by reaction of the raw Tetronic® terminal hydroxyl 
groups with acryloyl chloride. All glassware was cleaned with sodium hydroxide 
solution, rinsed with DI water followed by one acetone rinse, and completely dried in a 
60°C oven overnight. T1107 (30 g) was dehydrated by azeotropic distillation with 
toluene over two hours in an oil bath at 130°C, which was then allowed time to reflux 
and then subsequently removed by rotary evaporation (Buchi Rotavapor®, Switzerland) 
at 90°C. After cooling to room temperature, dehydrated T1107 was dissolved in 120 ml 
of dry dichloromethane and TEA (4 mmol, 1.115 ml) was added. On an ice bath, acryloyl 
chloride (8 mmol, 1.30 ml) in 60 ml of dry dichloromethane was then added dropwise 
over two hours and the reaction was allowed to continue at room temperature for 24 
hours. The reactant was filtered through celite fine 500 to remove TEA-HCl salt, and then 
paper-filtered to remove the celite. The solvent was removed by rotary evaporation at 
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room temperature. The residue was precipitated in 500ml of cold ethyl ether (-20°C), 
recovered by filtration, and dried under vacuum for a few hours. The product was 
redissolved in dry dichloromethane (300ml), washed repeatedly with 30ml of 10% w/v 
sodium bicarbonate solution until the pH was neutral, and then washed with deionized 
water (30 ml each) until the pH of the water faction was neutral. Next, the product was 
dehydrated with anhydrous sodium sulfate until the solution became clear. After paper 
filtration, the remaining solution (dichloromethane+ product) was decanted and removed 
by rotary evaporation at 25°C. The residue was precipitated and washed 3 times with cold 
ethyl ether (-20°C). The final product was recovered by filtration and dried in a vacuum 
desiccator overnight. The final structure and acrylation efficiency (%) were determined 
by 
1
H-NMR (Bruker Avance-300MHz) using a CDCl3 (chloroform) solvent.
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b. Preparation of T304-acrylate 
T304-acrylate was synthesized in a similar manner to T1107-acrylate with minor changes 
to account for reduced thermal stability and different solubility properties. Prior to 
experimentation, unmodified T304 was dissolved in dichloromethane, subjected to rotary 
evaporation and precipitated in hexane to test product recoverability. Following the initial 
reaction setup, the residue was precipitated in a total volume of 500ml of the cold 
hexane/ethyl ether (50/50 volume ratio), and stored at -20°C to allow the precipitated 
product to settle overnight. After approximately 24 hours, the hexane/ethyl ether 
supernatant solution was quickly and gently decanted and the product was redissolved in 
300 ml dichloromethane. Subsequently, the solution was washed repeatedly with 30 ml of 
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10% w/v sodium bicarbonate solution until the pH was neutral. This was followed by 
deionized water washes with 30 ml each until the pH of the water fraction was neutral, and 
the remaining product was dried with anhydrous sodium sulfate (approximately 4-6 times 
or until the solution became clear). Relatively small amounts of sodium sulfate was used 
in order to preserve as much of the product as possible. The product dissolved in 
dichloromethane was again subjected to rotary evaporation at 30°C and concentrated in 
the presence of 2 chips of 4-methoxyphenol. The residue was precipitated in a total 
volume of 500ml of hexane/ethyl ether and washed 3 more times with cold ethyl ether. 
The final product was recovered by decanting of the ethyl ether and dried under vacuum 
within a desiccator at 4°C for 6 to 8 hours. 
1
H-NMR was performed to analyze the final 
structure and acrylation efficiency (%) using 25 mg of product in 1 ml chloroform solvent 
(Cho and Cribb). 
 
C. Mechanical Testing of Tetronic® Adhesive  
Prior to mechanical testing, the appropriate weight of Tetronic® acrylates (Table 3.2) was 
first mixed with 1ml of PBS (50mM) on a rocker in a cold room, protected from light for 
1-2 days. 
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Table 3.2: T304-acrylate/T1107-acrylate blend ratios with corresponding DTT amounts 
 
a. Testing with a Model Tissue 
 Collagen casing was sectioned into ½ inch-wide strips using a previously created printed 
template and placed in a fixture that maintained end-to-end contact between two pieces 
(Figure 3.2). The strips were then hydrated in PBS within a 37°C water bath for one hour. 
 
Figure 3.2 End-to-End Configuration  
 For testing of each specimen, 50 microliters of T304-acrylate/T1107-acrylate blend was 
mixed with appropriate volumes of dithiothreitol (DTT) solution (10%) according to Table 
3.2 and vortexed until the solution crosslinked reached a certain viscosity, where it formed 
a gel-like substance, but was still in a liquid enough state for extraction by a 1 cc syringe. 
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The solution was judged to be in this “gel-like” state” when it did not flow within the 
mixing tube when subjected to tube inversion. Reproducibility was created through 
application of set vortex speeds correlating to gelation times among samples from the same 
Tetronic® blend. 50 µl of the mixture was then applied to the joint between the two pieces 
of collagen casing and allowed to cure under hydrated conditions in the 37°C water bath for 
30-45 min. Immediately before testing, specimen thickness was measured using a digital 
caliper. Using an MTS Synergie 100 (Figure 3.3) with a 10 N load cell, specimens were 
subjected to uniaxial tensile load at a rate of 5 mm/min until bonded joints broke. To avoid 
slippage, the ends of the specimen were wrapped with sandpaper (P400 grade) within the 
grips of the testing system. The data were reported as maximum tension to failure (N/cm). 
 
Figure 3.3: Tensile Testing Configuration 
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D. Viscoelastic Characterization of T304 and T1107 
a. Gelation Analysis 
To characterize the viscoelastic behavior of the Tetronic® hydrogels, unmodified 
(reverse thermal gelation) and acrylated (tandem crosslinking via reverse thermal gelation 
and Michael-type addition)12, T304 and T1107were dissolved in PBS at three different 
ratios of 100/0, 0/100, and 50/50 (at 30wt % and 50wt % concentration). 
1. Reverse Thermal Gelation 
Rheological analysis on unmodified Tetronic® macromers was performed using the 
AR2000 rheometer (TA Instruments, Newcastle, DE) with a parallel plate configuration 
(40 mm diameter). 60 µL of the test specimens were placed on the bottom plate (pre-
cooled to 4°C via ice bath), and then the top plate was lowered to create a 0.15 mm gap 
between the two plates. A temperature sweep from 4-40°C at 2°C/min was conducted at a 
constant frequency of 0.1 Hz. The temperature at which the storage (G’) and loss (G’’) 
moduli met was determined as the gelation point.
12
 
2. Tandem Crosslinking 
Parallel plate geometry was used again to analyze the crosslinking characteristics of 
acrylated Tetronic® macromers. The macromers were dissolved in PBS and then 
covalently crosslinked with DTT, a donor of the thiol group. The T304-acrylate/T1107-
acrylate solutions (60 µl of 100/0, 50/50 at 30 and 50wt %, 0/100 only at 30wt %) and 
DTT (10µl stored at 4°C until testing) were mixed and vortexed at room temperature. The 
mixture was placed on the bottom plate (pre-warmed to 37°C) of the AR2000 rheometer, 
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and the top plate was lowered to create a 0.15 mm gap between the two plates. 
Oscillatory shear strain of 1% was applied immediately at a constant frequency of 0.1 Hz. 
Storage and loss moduli were recorded as a function of time and gelation time was 
determined as the instance at which the lines for G’ and G” crossed over.12 
 
E. Ex Vivo Adhesive Testing on Rat Bladder 
Rat bladders were obtained from Pel-Freez Biologicals Inc. (Rogers, AR) and stored in 
30% sucrose solution at 4°C until testing. Prior to testing, a small, approximately 2 mm 
puncture was made on the dome of the bladder using an 18 gage needle. Using a 1 cc 
syringe, the Tetronic®/DTT mix (500 µl to 50 µl ratio) was applied to the hole and 
allowed to cure for 1 hour within a saline solution-containing petri dish in the 37°C water 
bath. After curing, the rat bladder was mounted via sutures and superglue on a shaved 18 
gage needle within a plastic container which was filled with saline solution until the 
bladder was submersed. The specimen was subjected to increasing intravesicular pressure 
using a Harvard Apparatus 11 Plus Pump (Harvard Apparatus; Hollison, MA) and a 60 
ml syringe at a flow rate of 0.1 ml/min until failure, which was evidenced by saline 
solution colored with calcein blue dye, indicating leakage. 
 
F. Statistical Analysis 
Quantitative data for maximum tension and maximum intravesicular pressure withstood 
by the Tetronic®-based adhesive were statistically analyzed using the commercial 
statistics software, SigmaStat 3.5. Following a one-way analysis of variance (ANOVA) 
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test, when statistical significance was observed, post-hoc comparisons were made using 
the Tukey method. Data sets with p values of less than 0.05 were considered to be 
statistically significant.  
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CHAPTER FOUR 
RESULTS 
A. 1H-NMR (CDCl3) Characterization of Tetronic® Acrylate 
T1107-acrylate (unmodified: Figure 4.1, acrylated: Figure 4.2) and T304-acrylate 
(unmodified: Figure 4.3, acrylated: Figure 4.4) were characterized via NMR 
spectroscopy, with peaks present at locations including δ= 1.2 (PPO CH3), 3.65 (PEO 
CH2), 4.32 (-CCH2OC (=O)), and 5.8-6.4 (2H, acrylic –CH2) ppm. The acrylation 
efficiency conversion percentage, calculated based on the ratio of the integrals of the 
PEG backbone (δ = 3.4~3.7) and the acrylate peaks, (δ = 5.8–6.4)12 were 93-95% for 
T1107-acrylate and 62-74% for T304-acrylate over two synthesis reactions for each 
Tetronic® type (Table 4.1). 
Table 4.1: Result summary of acrylation for Tetronics (mean± SD; n=2 reactions) 
Tetronic Type 
Average 
Acrylation 
Conversion 
Acquired via 
NMR Spectra 
Average Overall 
Product Yield 
(%) 
T304 68±8.5% 53±7.1% 
T1107 94±1.4% 73±8.9% 
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PEO/PPO Backbone 
Figure 4.1: 
1
H-NMR spectrum for unmodified T1107 (T1107: n = 60, m = 19) 
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Acrylate Groups 
PEO/PPO Backbone 
 
Methyl Group 
Figure 4.2: Tetronic® structure (T1107: n =60, m =19) and 
1
H NMR 
spectrum of T1107-acrylate 
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Figure 4.3: 
1
H-NMR spectrum for unmodified T304 (T304: n =3.7, m =4.3) 
PEO/PPO Backbone 
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Acrylate 
Groups 
PEO/PPO Backbone 
Methyl Group 
Figure 4.4: 
1
H NMR spectrum of T304-acrylate (T304: n =3.7, m =4.3) 
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B. Mechanical Testing of Tetronic® Adhesive 
The end-to-end tensile testing of collagen sheets bonded with Tetronic® adhesives 
revealed that at 40wt % (w/v), T304-acrylate/T1107-acrylate at 75/25 and 50/50 ratio 
blends exhibited a similar adhesion strength to T304-acrylate alone (p > 0.05) with an 
average maximum tension of 0.41 ± 0.06 (mean ± SEM, n=6) and 0.43 ± 0.03 N/cm 
(n=6), respectively, compared to 0.32 ± 0.07 N/cm (n=3) (Figure 4.5). In comparison, 
at 50wt %, the adhesive strengths were also similar (p > 0.05) for all three blends tested 
(T304-acrylate alone: 0.59 ±0.07 N/cm for n=3, 50/50: 0.56 ± 0.05 N/cm for n=6, and 
75/25: 0.52 ± 0.08 N/cm for n=3), which were greater (but not significantly) than that 
of the 40wt % formulations. The highest strength value achieved was for the 75/25 
T304-acrylate/T1107-acrylate group at 60wt % with a value of 0.65 N/cm ±0.06 N/cm 
(n=6), which was similar to the 50wt % blend groups, but exhibited significantly 
stronger (p < 0.05) adhesive strength than the other 50/50 blend ratio groups at both 40 
and 50wt %. There was also significant statistical difference among the 75/25 blend 
ratios for 40, 50, and 60wt %.
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Figure 4.5: End-to-End Testing Mechanism for T304-acrylate/T1107-acrylate 
ratios at 40wt %, 50wt %, and 60wt% (ratio/wt%), (n=6 for 75/25/40 50/50/40, 
50/50/50 and 75/25/60; n=3 for all other groups). Letters indicate significant 
difference between groups. 
34 
 
C. Viscoelastic Characterization of Tetronic® 
 
a. Gelation Analysis 
1. Reverse Thermal Gelation 
A temperature sweep from 4-40°C at 2°C/min was performed for the 100% T304 (at 30 
and 50wt %), 100% T1107 (at 30wt %) and a 50/50 blend (at 30 and 50wt %). Sol-gel 
transition temperatures (at which the storage (G’) and loss (G”) moduli met) were 
20.05±0.28°C for 100% T1107 and 36.2±1.64°C for the 50/50 blend at 30wt %. In 
contrast, gelation temperatures at 50wt % for the 50/50 blend were 36±1.03°C (Figure 
4.6) and 34.7±0.45°C (Figure 4.7) for the 100% T304 (Table 4.2). Data were not 
acquired for 100% T1107 at 50wt % and 100% T304 at 30wt %. as it either gelled too 
fast to test or did not gel within the temperature range tested. 
Table 4.2: Sol-gelation temperature of three Tetronic® blends %  
for a temperature sweep of 4-40°C (n=2) 
T304/T1107 
composition (total 
100%) 
Reverse Thermal 
Gelation: Gelation 
Point (°C) @ 
30wt% 
Reverse Thermal 
Gelation: Gelation 
Point (°C) @ 
50wt% 
100/0 N/A 36.0±1.03 
50/50 36.2±1.64 34.7±0.45 
0/100 20.1±0.28 N/A 
  
 
35 
 
 
 
Figure 4.6: Temperature sweep of 50/50 blend  
of T304-acrylate/T1107-acrylate at 50wt % 
at 50wt % 
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Figure 4.7: Temperature sweep of 100% T304-acrylate at 50wt %. 
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2. Tandem Crosslinking 
The gelation times were measured for three blends of T304-acrylate/T1107-acrylate 
at 50wt % when covalently crosslinked with DTT at 30 and 50wt%. The 100% 
T1107-acrylate’s gelation time was 26.6±2.28 seconds for 30wt %, but did not yield 
viable results at 50wt % due to rapid gelation. Gelation times 7 minutes and 19 
minutes on average (Table 4.3) for the 50/50 blend and 100% T304-acrylate at 30wt 
% (n=2), (Figure 4.8) respectively. In comparison, the average was 5 minutes and 11 
minutes for the same blend ratios at 50wt %. 
Table 4.3: Gelation times of three Tetronic® blends when crosslinked with DTT 
(n=2) 
T304-acrylate/T1107 -
acrylate composition 
(total 100%) 
Tandem Crosslinking: 
Gelation Time (s) @ 
30wt% 
Tandem Crosslinking: 
Gelation Time (s) @ 
50wt% 
100/0 1143.8±12.14 629.3±6.02 
50/50 474.1±17.31 304.5±8.49 
0/100 26.6±2.28 N/A 
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  Figure 4.8: Chart of 100% T304-acrylate subjected  
to oscillatory shear until gelation at 30wt % 
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D. Ex Vivo Adhesive Testing on Rat Bladder 
Rat bladders with approximately 2 mm punctures sealed with 100% T1107-acrylate at 
30wt % withstood an average of 29.91±3.21 cm H2O before failure (n=3). In contrast, 
T304-acrylate/T1107-acrylate (50/50) at 50wt % withstood significantly (p<0.05) 
higher pressure at an average of 45.45±3.96 cm H2O (mean ± SEM, n=5) (Figure 4.9)
40 
 
 
Figure 4.9: Effect of intravesicular pressure-loading rat bladder punctures 
sealed with two different Tetronic® adhesives (n=3 or 5) 
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CHAPTER FIVE 
DISCUSSION 
A. Characterization of Tetronic® Acrylate 
The goal of the present study was to investigate the effect of blending a low MW T304 on 
overall bulk strength of a Tetronic® 1107-based tissue adhesive, which was previously 
investigated 
12,39,40,41
 For T1107, the 94 ±1.41 % average percentage conversion of the 
terminal hydroxyls to acrylates obtained in the present study was on par with that reported 
previously by Cho et (97% average)
12
, indicating that a similar level of chemical 
crosslinking and bulk strength of this component could be expected. In contrast, average 
acrylate conversion percentage for T304 was 68% ± 7.49 with a relatively low product 
yield compared to T1107-acrylate (53% vs. 73%), which may be attributed to the 
differences in physical state (solid for T1107 and liquid for T304 at RT). We speculated in 
early stages of the study that large amounts of T304 were lost during the sodium sulfate 
drying and ethyl ether/hexane wash steps of the acrylation process based on differences in 
the amount of product observed before and after these specific steps. Therefore to improve 
both acrylation efficiency and product yield for T304, we modified the synthesis protocol 
to include longer reflux durations for the distilled product, efficient rotary evaporation by 
allowing more time to elapse in order to fully evaporate either toluene or DCM, and more 
sodium sulfate drying steps at smaller volumes. Using this modified protocol, T304-
acrylate product yield almost tripled from 17% to an average of 53%. Additionally, 
acrylation percentage increased from 39% to an average of 68%. Further modification of 
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the synthesis process such as even slower addition of acrloyl chloride to the product may 
lead to an even higher acrylation percentage for the T304-acrylate. 
 
B. Mechanical Testing of Tetronic® Adhesive 
The results of the present study demonstrate that T304-/T1107-acrylate blends (Figure 
4.5) were mechanically stronger compared to the T904-/T1107-acrylate blends previously 
tested (unpublished data, Appendix C, Figure C.1). More specifically, the average 
maximum adhesive strengths at a 75/25 and 50/50 ratio of T304-/T1107-acrylate values, 
0.41 ± 0.06 N/cm and 0.43±0.03 N/cm (Figure 4.5), were much greater than the same 
ratios for T904-/T1107-acrylate (40wt %), 0.15±0.02 N/cm (n=9) and 0.07±0.01 N/cm 
(n=9) (Figure C.1), respectively. A similar trend was also observed at 50wt %. 
Differences in strength between the T304 and T904 are attributed to the much lower MW 
of the T304 (1650 Da vs 6700 Da), which enables more Tetronic® content to be 
incorporated into the hydrogel adhesive. Among the blends tested to date, the 75/25 ratio 
of T304-/T1107-acrylate at 60wt % exhibited the highest bulk strength, corroborating with 
our original hypothesis that the higher content of hydrogel by incorporation of the low 
MW T304-acrylate would increase the strength of the tissue adhesive. Statistical analysis 
verified this by showing significant differences (p<0.05) among various weight 
percentages of the same blend ratio (i.e. 75/25 at 40, 50, and 60wt % and 50/50 at 40 and 
50wt %), but not among specific blend ratios within one weight percentage category. 
However, it must be noted that T1107-acrylate did contribute to the bulk strength of the 
adhesive as evidenced by increases from the 75/25 to 50/50 ratios by manipulating the 
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amount of T1107-acrylate content for both 40wt % (0.41 ± 0.06 N/cm to 0.45 ± 0.05 
N/cm) and 50wt % (0.52 ± 0.08 N/cm to 0.56 ± 0.05 N/cm. Yet, a “ceiling” has been 
established for how much T1107 content can be included in the surgical adhesive (30wt 
%) before rapid thermal gelation occurs. Catalyzed by the large molecular weight of 
15,030 Da and PEO/PPO ratio of the gel, T1107 has a high capacity for reverse thermal 
gelation in both its unmodified and modified forms.
12
 This theory is also illustrated in the 
fact that mechanical testing results were unattainable for high weight concentrations of the 
T1107 (i.e. 25/75 T304-/T1107-acrylate at 40wt % and up) due to gelling of the Tetronic® 
hydrogel before it could be applied to the collagen casing surface.  
 
To estimate a target strength for the Tetronic®-based adhesive, the Law of LaPlace was 
applied at physiological conditions of 40 cm H2O voiding pressure, 600 ml capacity, and 
12 cm distended bladder diameter. Calculated as a function of bladder thickness, diameter 
and intravesicular pressure, it was determined that the surgical tissue adhesive must 
withstand tensions approximately between 3.2-4.8 N/cm. While these values were not 
reached in the present study, failure during mechanical testing was observed as “cohesive 
failure” as the material broke at the interface between the two collagen strips, but was still 
present on the surfaces of the debonded pieces. This type of failure indicates that the 
adhesive strength of the Tetronic® hydrogel is stronger than cohesive strength. It is 
predicted based on results generated by mechanical testing of the adhesive that higher 
weight percentages of T304-acrylate (in the range of 70-80wt %) in the hydrogel-based 
tissue adhesive will aid in yielding even higher bulk strengths. Additionally, it is projected 
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that bond strength can also be improved through copolymerization of the Tetronic® 
hydrogels with PEG/dextran hydrogels or acrylate/aldehyde difunctional poloaxmers, in 
addition to functionalizing the Tetronic® hydrogel with catechols.
12,27,28,41,45,46 
 
C. Viscoelastic Characterization of Tetronic® 
Concentrated aqueous solutions of Tetronic® have been shown to undergo physical 
gelation at temperatures in the 20-35°C range due to the hydrophobic transition associated 
with their PPO segments.
41
 At 30wt %, the 100% T1107 gelled at 20.05±0.28°C (Table 
4.2). In contrast, the 100% T304 at 30wt % did not gel under the temperature range tested 
in (4-40 C) as Cho et al. observed for the 100% T904 in a previous study, suggesting that 
both T304 and T904 lack reverse thermal gelation at relatively low concentrated 
solutions.
12
 Both the 100% T304 and 50/50 blend at 50wt %, however, transitioned from a 
liquid to solid state at physiological temperatures of 36±1.03°C and 34.7±0.45°C (Table 
4.2), respectively.
12 
Moreover, T304/T1107 at 30wt % and a 50/50 blend ratio gelled at a 
higher temperature, 36.2±1.64°C, than the same blend ratio for T904/T1107 which gelled 
at 23.67±1.22°C. This demonstrates that adhesives containing T304 can gel upon contact 
with tissue at physiological temperatures (37°C).
12
 Yet, it is projected that since the 100% 
T304 at 30wt % failed to gel at physiological temperatures, either a higher molecular 
weight Tetronic should be used in conjunction with the T304 or a higher weight 
percentage of T304 alone should be used to create the Tetronic®-based tissue adhesive. 
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The increase in gelation time with increasing T304-acrylate content observed in the 
present study (Table 4.3) is associated with the diminishing contribution of the T1107-
acrylate component to reverse thermal gelation.
12
 This is evidenced in the drastic 
difference in gelation times between the 50/50 blend (304.5±8.49 sec) and the 100% 
T304-acrylate (629.3±6.02 sec), demonstrating the impact T1107 has on gelation time. 
When comparing the gelation times for 100% T304-acrylate and the 100% T304-acrylate 
in Cho et al.’s study12, the 7.5-fold difference 153.33±5.77 sec versus 1144±12.1 sec, was 
thought to be attributed to the difference in acrylation efficiency (87% vs. 68 %), and in 
molecular weights. This was because neither product contained T1107, and the gelation is 
due mainly to the covalent crosslinking, mediated by the presence of DTT. Moreover, the 
present study demonstrated that the gelation time of the 50/50 blend at 50wt % was lower 
than that the same blend at 30wt %. These results illustrate the impact of hydrogel content 
and an increased number of crosslinking sites on the ability to adjust gelation time. 
Finally, since the Michael-type addition is a pH-dependent reaction, the gelation times and 
reaction rates for covalent crosslinking can be further tuned for desired applications by 
adjusting the pH of the solution reactants.
12
 
 
D. Ex Vivo Adhesive Testing on Rat Bladder 
Because the adhesive developed in the present study was originally meant for repair of 
bladder injuries, ex vivo testing was conducted using a custom device
44
 on rat bladders 
submersed in saline solution with the purpose of approaching more physiological 
conditions than tensile testing with tissue segments. The 50/50 blend of T304-
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acrylate/T1107-acrylate at 50wt % withstood pressures at an average of 45.45±3.96 cm 
H2O, higher pressures than the control group, the 100% T1107-acrylate at 30wt % 
(29.91±3.21 cm H2O). These results showed that this blend of Tetronic® adhesive was 
effective at sealing a rat bladder puncture at physiological pressures. However, further 
tests need to be conducted following repeated cycling of the bladder in order to measure 
long-term durability of the adhesive. It also must be noted that in the present study, only 
two blend ratios of T304-acrylate/T1107-acrylate were tested in these conditions. 
Therefore, it is predicted that blends with higher levels of Tetronic® contents (75/25 at 
60wt %), will withstand higher levels of intravesicular pressure. 
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CHAPTER SIX 
CONCLUSION 
The results from the present study demonstrated the impact of a low molecular weight 
Tetronic®, T304, on the bulk strength of a hydrogel-based bladder adhesive. Specifically, 
using T304 instead of T904 has allowed for a higher content of hydrogel to be 
incorporated into the Tetronic®-based adhesive, thus increasing the weight percentage to 
increase overall bulk strength. Additionally, the contribution of T1107 to the bulk 
strength and gelation time of the Tetronic®-based adhesive has been demonstrated. 
Therefore, further fine tuning of T304-acrylate/T1107-acrylate blends ratios as well as 
improving the acrylation efficiency of the T304 should allow for achieving the balance 
between high overall bulk strength and clinically relevant gelation times. 
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CHAPTER SEVEN 
LIMITATIONS AND FUTURE WORK 
A. Limitations and Potential Solutions 
a. Characterization of Tetronic® Acrylate 
 Acrylation efficiency of the T304 (68%) was lower in comparison to T1107 (94%) 
possibly due to rapid addition of acrloyl chloride. This conversion percentage may be 
improved by adding the acrloyl chloride much more slowly which will provide more 
time for the reaction and more efficient filtration of the TEA-HCl salt to remove 
excess chlorides. 
 Product yield of T304 was also low in comparison to T1107 mainly due to the 
product loss during the sodium sulfate drying steps. This could be improved by more 
sodium sulfate drying steps at smaller volumes. 
 In the present study, PBS was used to dissolve Tetronic® without further adjustment 
of pH. Since crosslinking rate of Tetronic®-acrylate is highly sensitive to pH 
variability, in future studies, pH levels of the T304 should be monitored(and adjusted 
accordingly) at regular intervals and maintained in the desired range (ideally 7.2-7.4) 
before it is used as a tissue adhesive. 
 
b. Mechanical Testing of Tetronic® Adhesive 
 Since the main goal of the present study was to improve the bulk strength of the 
Tetronic®-based adhesive, mechanical testing was performed in the end-to-end 
configuration. By completing shear adherence tests of T304-acrylate/T1107-acrylate 
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with the same blend ratios as T904-acrylate/T1107-acrylate previously tested, a direct 
comparison could be made as to how incorporation of T304 in the hydrogel-based 
adhesive improves the bond strength. 
 Tetronic® adhesives on collagen casings were cured under a hydrated condition for 
one hour prior to mechanical testing for all blend ratios and weight percentages to 
maintain consistency between the previous and present studies. Since the 
viscoelastic characterization demonstrated that gelation of T304/T1107 (50/50) 
occurs in 5 minutes, future mechanical testing may be performed with shorter curing 
times in order to be more clinically relevant. 
 
c. Viscoelastic Characterization of Tetronic® 
 Temperature sweep tests were only performed on unmodified Tetronic® solutions to 
characterize the reverse thermal gelation behavior of the polymers. Conducting these 
tests on modified Tetronic® macromer solutions would provide further insight into 
the effect of terminal acrylate groups on gelation temperatures. 
 
d. Ex Vivo Adhesive Testing on Rat Bladder 
 Pressure testing of rat bladders was limited to a single loading cycle until failure. 
Subjecting the rat bladder to repeated cycles of pressure loading will allow for 
assessing long-term strength and durability of the adhesive. 
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B. Future Work 
 Evaluating the swelling behavior of T304-acrylate  
o Rationale: In order to ensure the adhesive does not lose its mechanical 
strength or cause compression in surrounding tissues 
 Testing the hydrogel-based adhesive on the bladder both ex vivo and in vivo 
using larger animal models  
o Rationale: Tests on larger animal models are a necessary step after small 
animal models (rats) before ultimately moving onto clinical trials. 
 Incorporation of a controlled biodegradable feature to the formulation 
o Rationale: Tetronic® polymers go through hydrolytic degradation, so a 
feature that enables controlled biodegradation will extend the amount of 
time for which the adhesive will be effective. 
 Development of a user-friendly application tool for surgical procedures 
o Rationale: Ease of application is one of the characteristics of an ideal 
surgical adhesive. The application mechanism must take into account the 
two separate parts of the hydrogel-based adhesive: the Tetronic® 
component and the thiol-containing crosslinker component. 
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Appendix A: Additional Literature Review on Tissue Adhesives 
a. Cyanoacrylate 
1. Leggat et al. (2007) 
The application of adhesive cyanoacrylate film strengthens by rapid polymerization, 
usually within 5–60 seconds, catalyzed by hydroxyl groups on the surface being glued. 
Earlier research work proposed that cyanoacrylate adhesives may generate lipid 
hydroperoxides, which in turn activate prostaglandin and thromboxane biosynthesis. 
These adhesives have also demonstrated the capacity to oxidize and lyse cell membranes, 
somewhat explaining the reason behind the presence of particular thrombotic events 
associated with necrosis when cyanoacrylates are used in vivo. In general, cyanoacrylate 
has been shown to cause inflammation and tissue necrosis in vivo when used as a tissue 
adhesive.
20 
 
2. Mizrahi et al. (2011) 
Methodology in one study involved synthesizing the cyanoacrylates by condensation and 
Knoevenagel reaction followed by characterization of the product by 
1
H NMR 
spectroscopy. Mechanical testing was initially performed using an Instron universal 
testing machine on aluminum specimens, with 5 microliters of the monomer applied to 
each of the two specimens. The peak detachment force (N) and modulus were determined 
after the probe was withdrawn at a rate of 0.1 mm/min. Similar experiments were 
performed using strips of fresh skin harvested from 10 rats. 25 microliters of each glue 
type was applied to cross-sectional cuts of 2 x 6 cm strips of skin with specimens 
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stretched at a rate of 10 mm/min. Furthermore, the cytotoxicity of the different 
cyanoacrylates was evaluated by exposing cells to the polymerized glues either by direct 
contact (‘‘direct’’) or indirectly by exposing cells to the medium (DMEM) in contact 
with the polymerized glues (‘‘indirect’’). And finally to test biocompatibility, Skin 
incisions of 1.5 cm were made in anesthetized rats with 20 microliters of cyanoacrylate 
applied to the resulting pouch. After 12 days, the rats were killed via carbon dioxide, and 
the skin surrounding the glues was analyzed using histology.
14
 
 
Results showed that yields of the synthesized monomers reduced with increasing side-
chain length, possibly due to higher boiling points and larger degrees of side-chain 
entanglement with increasing length. For mechanical testing, load values at rupture were 
between 20 and 30 Newtons, consistent with previous studies for other cyanoacrylate 
glues used ex vivo. Also, increasing side chain length was proven to increase the elasticity 
of the polymer as well as decrease adhesive strength (although all strengths were still 
classified as “useful”. With regard to cytotoxicity, monomers with longer side chains had 
less toxicity both in vivo and in vitro. Biocompatibility findings demonstrated that 
animals injected with cyanoacrylates comprised of longer side-chains had inflammation 
without necrosis while those injected with monomers comprised of shorter side-chains 
displayed serious tissue responses with prominent inflammation and necrosis. 
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3. Mobley et al. (2002)  
The binding strength of cyanoacrylates improved when the octyl-2 isomer was introduced 
due to its approximately 4-fold three dimensional breaking strength increase in 
comparison with its predecessor. Another advantage of this newest cyanoacrylate type is 
that it possesses an antimicrobial activity that have been shown to have positive effects 
on posttraumatic laceration.
15 
 
4. Reese et al. (2001) 
Additionally, data acquired from numerous clinical trials have shown that rates of wound 
dehiscence, hematoma formation and infection in cyanoacrylate-based adhesives are 
nearly identical to those found in sutures repairs.
13 
 
b. BioGlue
 
1. Furst et al. (2005) 
One study sought to evaluate the amount of glutaraldehyde released from BioGlue, the 
effect of cytotoxicity on cultured cells (both in vivo and in vitro), and the local reaction of 
rabbit lung, liver and aortic tissues to BioGlue. In the rabbit lung and liver models, a 
fibrin sealant was used as the control group. With respect to experimental procedure, 
BioGlue was prepared according to manufacturer instructions, allowed to polymerize for 
2 minutes, and then overlaid with 5 ml of saline solution. The resulting supernatants were 
then harvested and analyzed to determine content of glutaraldehyde. The cytotoxic effect 
of BioGlue was evaluated by adding the supernatants to either human embryo fibroblasts 
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(MRC5) or mouse myoblasts (C2C12). In vivo toxicity was measured on three different 
tissues by applying BioGlue onto a rabbit partial lung resection, a liver abrasion, or an 
intact abdominal aorta. Transverse tissue samples were stained with hematoxylin and 
eosin and histologically assessed 2 and 7 days after application.
23 
 
2. LeMaire et al. (2002) 
To test their hypothesis, LeMaire et al. first subjected ten 4-week-old domestic piglets 
(8.0 ±1.4 kg) to general anesthesia. Next, under sterile conditions, the infrarenal 
abdominal aorta was exposed through a midline laparotomy after which the aorta was 
transected at the midpoint between the renal arteries and the bifurcation. A 2 mm ring of 
aorta was removed from the proximal stump and cut longitudinally to allow for accurate 
measurement of the aorta’s circumference. Finally, an end-to-end aorto-aortic 
anastomosis was performed with interrupted 6-0 polypropylene sutures. Following 
verification of patency using an aortogram, five piglets were assigned to either the 
BioGlue group or control group. For the experimental group, a layer of BioGlue was 
applied around the entire anastomosis as per manufacturer instructions. After a 7-week 
growth period, the aortas were excised for morphometric analysis and histopathology. 
Histologic sections of 5 microns were prepared using hematoxylin and eosin as well as 
Geske’ stains, while for the morphometric analysis, aortic growth was evaluated by 
calculating the changes in outer circumference and aortic area over the 7-week growth 
period. 
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Initial results from this study showed that weight gains were similar in both the 
experimental and control groups. Yet, in pigs treated with BioGlue, aortic circumference 
increased less, 1.5 ± 0.8 mm, versus 2.7 ±0.8 mm for the control group (p=0.054). 
Moreover, BioGlue animals developed a 33.9% stenosis of the aortic lumen area against 
3.7% in the controls (p =0.038). Histological results demonstrated normal postoperative 
changes in the anastomotic sections of the control animals, including suture granulomas 
and a mild increase in adventitial connective tissue. In comparisons, similar sections in 
the BioGlue animals showed macrophage infiltration, dystrophic calcification, and 
presence of foreign body giant cells. The group also found that the piglets treated with 
BioGlue showed evidence of major fibrosis in the area surrounding the aorta.
22
 
 
c. Fibrin Glue 
1. Radosevich et al. (1997) 
Fibrin glues are biological, biodegradable products that do not cause serious negative 
reactions of tissue or induce necrosis/inflammation, which is in contrast to synthetic 
sealants. Fibrin binds to biological tissues either by covalent, hydrogen or other 
electrostatic bonds. Additionally, fibrin binds covalently to fibronectin and collagen by 
way of factor XIIIa.
24 
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2. Cho et al. (2011) 
There are certain drawbacks with naturally derived products such as fibrin glue and 
BioGlue. These risks involve the possibility of viral transmission, hypersensitive 
reactions to bovine proteins, and relatively low mechanical properties.
12 
 
3. Traver et al. (2006) 
The composition of the commercial types of fibrin glue varies, but there are distinct 
similarities such as incorporation of a 2-vial system containing fibrinogen, thrombin, 
factor XIII, and calcium. The mechanism by which fibrin glue operates is actually a 
mimic of the final steps of the natural coagulation cascade experienced by the human 
body: thrombin activates factor XIII, which stabilizes the blood clot, by stimulating 
crosslinking of the fibrin chains to long fibrin strands. Preparation takes 15 minutes and 
application is performed using a double-barrel syringe system.
17 
 
4. Mobley et al. (2002) 
This type of tissue adhesive has the longest history, and therefore, the broadest range of 
applications. Recently, enhanced tensile strength by using pooled plasma has been shown 
to increase fibrinogen production leading to more versatility for fibrin products in facial 
reconstruction. Also, higher concentrations of thrombin in fibrin lead to quicker clot 
formation and are ideal for hemostasis. Finally, an advantage of the double-barrel syringe 
method of mixing is uniform mixing of the components, but disadvantages lie in 
complexity and needle clogging As a result, a more sophisticated system of application, 
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the Hemamyst aerosol spray device (Haemacure) is used. This is a gas pressurized system 
using pressures of 5 to 10 liters/ min. The components are mixed in a pressurized gas 
stream, allowing for more thorough mixing of the components compared to the older 
syringe systems.
15 
 
5. Reese et al. (2001) 
Fibrin glues have displayed the ability to be effective in cardiovascular surgery for 
hemostasis, sealing air leaks in lung procedures, control burn bleeding, and in treating 
lymphatic leaks in the neck. Additionally, they are the only type of tissue adhesives that 
promote healing.
13
 
 
6. Artzi et al. (2009) 
Fibrin glue contains an antiproteinase that in turn hinders the growth of vascular 
granulation tissue and healing of surgical anastomoses.
28
 It is also characterized as having 
relatively non-specific and minimally adhesive tissue interaction while demonstrating a 
mild tissue response.
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7. Shazly et al. (2008) 
Finally, fibrin glues are generally more biocompatible than cyanoacrylates, but introduce 
a moderate risk of infectious transmission due to their biological origins.
46
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d. Tetronic® 
1. Cho et al. (2011) 
Acrylated macromers were covalently crosslinked using dithiothreitol (DTT) as a donor of 
the thiol group. Solutions of T1107/T904 acrylate ratios and DTT at 4°C were mixed at a 
1:1 thiol:acrylate molar ratio(30% weight/volume final Tetronic® concentration). Also, 
viscosity of the poloaxmine solutions were was characterized at three different 
temperatures using a rheometer (Physical MCR 300). The macromers were also subjected 
to thermally-induced noncovalent gelation assessed by a tube inversion method. Tissue 
bond strength was examined using rat skin; various hydrogel solutions mixed with DTT 
were applied to a 1 cm x1 cm area of one skin strip and another skin strip was placed over 
it. Bonding strength was calculated as the maximum load divided by the bonded area. 
Tensile testing on all samples was performed after overnight equilibration at 4 and 37°C 
where samples were cut into dog-bone shaped and subjected to uniaxial testing on an MTS 
Synergie 100 machine at 20% strain and relaxation. Finally, cytotoxicity tests were 
conducted using normal human dermal fibroblasts.
12
 
 
In general, Tetronic®-based hydrogels are expected to bond to native tissue by way of 
mechanical interactions with the tissue microarchitecture. Additionally, they can bond 
through covalent crosslinking of free thiols present in ECM proteins. The amount of free 
thiols present may vary based on exposure time to DTT during gelation (larger time 
periods increase thiol number).
12 
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Appendix B: Complete Tetronic®/DTT Mixing Table  
 
Table B.1: Full Tetronic®/DTT mixing table (bolded  formulations used in 
mechanical testing) 
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Appendix C: Previous Mechanical Tests Using Tetronic® 
Unpublished results from previous experiments conducted in our lab are presented below 
(Figure C.1). The graphs display the maximum tension (N/cm) for n=9 tests per ratio and 
shear adherence (Pa) for n=6 tests per ratio achieved for various blend ratios of T904-
acrylate/T1107-acrylate. Maximum tension results were obtained via end-to-end tests 
while shear adherence testing followed a different protocol whereby a 4.9 mm-diameter 
circular defect was created in a wide, ¾ inch-wide collagen sheet and placed over a 
narrow, ½ inch-wide sheet with a stainless steel washer used to limit excessive spreading. 
Next, 75 µl of the Tetronic®/DTT mix was applied to the center of the defect to form a 
hydrogel rivet that maintained contact between the two sheets. Finally, a similar curing 
time and mechanical testing procedure as the end-to-end test was observed. 
Largest average maximum tension values achieved for end-to-end tests of T904-
acrylate/T1107-acrylate ratios were 0.43± 0.06 N/cm (mean ± SEM) at a ratio of 50/50 
and 0.28± 0.04 N/cm for a ratio of 75/25, respectively at 50wt %. In comparison, the 
highest average maximum shear adherence values were 18,123 ± 1650 Pa for the 75/25 
ratio and 13,801 ± 1733 Pa at a ratio of 50/50, also both at 50wt %. However, the PEG 
control was found to have the largest value for these tests with 23, 152 ± 8782 Pa. 
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